What question did this study set out to answer?

To evaluate the prognostic significance of flow cytometric minimal residual disease (MRD) across multiple treatment time points and its relationship with standard clinical and genetic risk factors in childhood precursor B-cell acute lymphoblastic leukemia.

April 4, 2008BloodOpen Access

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

View Full Paper

Ask AI

Bookmark

To evaluate the prognostic significance of flow cytometric minimal residual disease (MRD) across multiple treatment time points and its relationship with standard clinical and genetic risk factors in childhood precursor B-cell acute lymphoblastic leukemia.
Analyzed flow cytometric minimal residual disease (MRD) in peripheral blood (day 8) and bone marrow (day 29 end-induction and end-consolidation) across clinical trials NCT00005585, NCT00005596, and NCT00005603.
Included 2,143 pediatric patients diagnosed with precursor B-cell acute lymphoblastic leukemia treated by the Children's Oncology Group.
Patients with 0.01% to 0.1% day-29 marrow MRD had worse 5-year event-free survival (EFS) than MRD-negative patients (59% ± 5% vs 88% ± 1%).
Detectable MRD at the end of consolidation was associated with a 5-year EFS of 43% ± 7%, and day-29 marrow MRD was the strongest prognostic variable in multivariate analysis.
A subset of patients (12%) exhibiting all favorable clinical, genetic, and day-8 and day-29 MRD-negative features achieved a 97% ± 1% 5-year EFS with nonintensive therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial reveals that minimal residual disease strongly predicts relapse across risk groups in pediatric B-cell leukemia, highlighting its role as a key prognostic marker.

Cite This Study

Borowitz et al. (2008) studied this question.

synapsesocial.com/papers/6a105f85d13714ec96ffb392 https://doi.org/10.1182/blood-2008-01-132837

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals that minimal residual disease strongly predicts relapse across risk groups in pediatric B-cell leukemia, highlighting its role as a key prognostic marker.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

Key Points

Discussion

Implication

Cite This Study

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider